Mapping the human amylase gene cluster on the proximal short arm of chromosome 1 using a highly informative (CA)n repeat

The human amylase gene cluster includes a (CA)n repeat sequence immediately upstream of the [gamma]-actin pseudogene associated with the AMY2B gene. Analysis of this (CA)n repeat by PCR amplification of genomic DNA from the 40 families of the Centre d'Etude du Polymorphisme Humain (CEPH) reference panel revealed extensive polymorphism. A total of six alleles with (CA)n lengths of 16-21 repeats were found. The average heterozygosity for this polymorphism was 0.70. Multipoint linkage analysis showed that the amylase gene cluster is located distal to the nerve growth factor [beta]-subunit gene (NGFB) and is within 1 cM of the anonymous locus D1S10. The amylase (CA)n repeat provides a convenient marker for both the physical and the genetic maps of human chromosome 1p.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/28584/1/0000391.pd

Taql and Mspl RFLPs are detected by the human 2,3-biphosphoglycerate mutase (BPGM) cDNA

No abstract availabl

MspI RFLP detected by a ZNF-40 cDNA sequence

Source/Description: 1.6 kb EcoRI fragment from a 5' cDNA clone (designated 4b) of the human ZNF-40 locus. ZNF-40 (MBP-1) (PRDII-BFI) encodes the class I major histocompatibility complex (MHC) enhancer binding protein 1 (2)

Enterocytic Differentiation of cultured human colon cancer cells by replacement of glucose by galactose in the medium

International audienc

REVIEW Open Access Considerations in the development of circulating

This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic steps in biomarker development–analytical and clinical validation and clinical qualification for specific contexts of use. To that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Dru

Cell-free DNA approaches for cancer early detection and interception

Rapid advancements in the area of early cancer detection have brought us closer to achieving the goals of finding cancer early enough to treat or cure it, while avoiding harms of overdiagnosis. We evaluate progress in the development of early cancer detection tests in the context of the current principles for cancer screening. We review cell-free DNA (cfDNA)-based approaches using mutations, methylation, or fragmentomes for early cancer detection. Lastly, we discuss the challenges in demonstrating clinical utility of these tests before integration into routine clinical care